Does the media refer more to JNJ or EBS?

In the previous week, Johnson & Johnson had 84 more articles in the media than Emergent Biosolutions. MarketBeat recorded 89 mentions for Johnson & Johnson and 5 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.11 beat Emergent Biosolutions' score of 0.63 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 62 Very Positive mention(s) 12 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Emergent Biosolutions 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NVAX or EBS?

In the previous week, Novavax had 3 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for Novavax and 5 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.63 beat Novavax's score of 0.33 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INVA or EBS?

In the previous week, Innoviva had 2 more articles in the media than Emergent Biosolutions. MarketBeat recorded 7 mentions for Innoviva and 5 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.63 beat Innoviva's score of 0.08 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EBS or MNKD?

In the previous week, MannKind had 8 more articles in the media than Emergent Biosolutions. MarketBeat recorded 13 mentions for MannKind and 5 mentions for Emergent Biosolutions. MannKind's average media sentiment score of 0.73 beat Emergent Biosolutions' score of 0.63 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EBS or ZBIO?

In the previous week, Emergent Biosolutions had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 5 mentions for Emergent Biosolutions and 2 mentions for Zenas BioPharma. Emergent Biosolutions' average media sentiment score of 0.63 beat Zenas BioPharma's score of 0.47 indicating that Emergent Biosolutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Emergent Biosolutions (EBS) Competitors

$7.96 -0.04 (-0.45%)

Closing price 03:59 PM Eastern

Extended Trading

$7.84 -0.12 (-1.52%)

As of 07:43 PM Eastern

Compare

EBS vs. JNJ, NVAX, INVA, MNKD, and ZBIO

Should you buy Emergent Biosolutions stock or one of its competitors? MarketBeat compares Emergent Biosolutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Emergent Biosolutions include Johnson & Johnson (JNJ), Novavax (NVAX), Innoviva (INVA), MannKind (MNKD), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Johnson & Johnson had 84 more articles in the media than Emergent Biosolutions. MarketBeat recorded 89 mentions for Johnson & Johnson and 5 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.11 beat Emergent Biosolutions' score of 0.63 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	62 Very Positive mention(s)	12 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Emergent Biosolutions	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.05	$26.80B	$8.65	27.39
Emergent Biosolutions	$742.90M	0.55	$52.60M	-$0.28	N/A

Johnson & Johnson has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market.

Johnson & Johnson currently has a consensus price target of $253.04, suggesting a potential upside of 6.82%. Emergent Biosolutions has a consensus price target of $12.00, suggesting a potential upside of 50.68%. Given Emergent Biosolutions' higher probable upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Johnson & Johnson has a net margin of 21.83% compared to Emergent Biosolutions' net margin of -1.27%. Johnson & Johnson's return on equity of 32.60% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Novavax?

Novavax (NASDAQ:NVAX) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Novavax currently has a consensus price target of $12.13, indicating a potential upside of 39.85%. Emergent Biosolutions has a consensus price target of $12.00, indicating a potential upside of 50.68%. Given Emergent Biosolutions' stronger consensus rating and higher probable upside, analysts plainly believe Emergent Biosolutions is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

53.0% of Novavax shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Novavax had 3 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for Novavax and 5 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.63 beat Novavax's score of 0.33 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Emergent Biosolutions has a net margin of -1.27% compared to Novavax's net margin of -14.73%. Emergent Biosolutions' return on equity of 10.76% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Novavax has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, suggesting that its stock price is 133% more volatile than the broader market.

Novavax has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.27	$440.30M	-$0.58	N/A
Emergent Biosolutions	$742.90M	0.55	$52.60M	-$0.28	N/A

Summary

Emergent Biosolutions beats Novavax on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Innoviva?

Innoviva (NASDAQ:INVA) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Innoviva presently has a consensus price target of $36.20, indicating a potential upside of 60.60%. Emergent Biosolutions has a consensus price target of $12.00, indicating a potential upside of 50.68%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Innoviva is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Innoviva has a net margin of 119.89% compared to Emergent Biosolutions' net margin of -1.27%. Innoviva's return on equity of 33.33% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Innoviva has higher earnings, but lower revenue than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.75
Emergent Biosolutions	$742.90M	0.55	$52.60M	-$0.28	N/A

In the previous week, Innoviva had 2 more articles in the media than Emergent Biosolutions. MarketBeat recorded 7 mentions for Innoviva and 5 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.63 beat Innoviva's score of 0.08 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Innoviva beats Emergent Biosolutions on 12 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to MannKind?

Emergent Biosolutions (NYSE:EBS) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Emergent Biosolutions presently has a consensus target price of $12.00, suggesting a potential upside of 50.68%. MannKind has a consensus target price of $8.97, suggesting a potential upside of 151.23%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Emergent Biosolutions has a net margin of -1.27% compared to MannKind's net margin of -6.63%. Emergent Biosolutions' return on equity of 10.76% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
MannKind	-6.63%	-11.21%	-3.92%

Emergent Biosolutions has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Emergent Biosolutions has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.55	$52.60M	-$0.28	N/A
MannKind	$348.97M	3.16	$5.86M	-$0.07	N/A

In the previous week, MannKind had 8 more articles in the media than Emergent Biosolutions. MarketBeat recorded 13 mentions for MannKind and 5 mentions for Emergent Biosolutions. MannKind's average media sentiment score of 0.73 beat Emergent Biosolutions' score of 0.63 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Emergent Biosolutions beats MannKind on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Zenas BioPharma?

Emergent Biosolutions (NYSE:EBS) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Zenas BioPharma has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Zenas BioPharma	N/A	-99.99%	-58.06%

78.4% of Emergent Biosolutions shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Emergent Biosolutions had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 5 mentions for Emergent Biosolutions and 2 mentions for Zenas BioPharma. Emergent Biosolutions' average media sentiment score of 0.63 beat Zenas BioPharma's score of 0.47 indicating that Emergent Biosolutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions presently has a consensus target price of $12.00, suggesting a potential upside of 50.68%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 140.42%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Emergent Biosolutions has higher revenue and earnings than Zenas BioPharma. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.55	$52.60M	-$0.28	N/A
Zenas BioPharma	$10M	116.29	-$377.74M	-$8.47	N/A

Emergent Biosolutions has a beta of 2.33, indicating that its share price is 133% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

Summary

Emergent Biosolutions beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$412.77M	$3.30B	$6.64B	$22.98B
Dividend Yield	N/A	2.33%	2.67%	4.11%
P/E Ratio	-28.44	10.40	20.93	27.78
Price / Sales	0.55	297.55	508.64	21.22
Price / Cash	2.18	118.24	42.36	23.83
Price / Book	0.80	8.06	10.47	4.64
Net Income	$52.60M	$23.83M	$3.56B	$1.07B
7 Day Performance	-2.70%	-2.82%	-1.11%	-0.71%
1 Month Performance	-16.19%	2.22%	1.28%	0.06%
1 Year Performance	22.62%	37.70%	21.20%	21.50%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	2.4766 of 5 stars	$7.96 -0.5%	$12.00 +50.7%	+20.4%	$412.77M	$742.90M	N/A	2,420	News Coverage
JNJ Johnson & Johnson	4.3246 of 5 stars	$223.90 -0.6%	$253.04 +13.0%	+49.8%	$542.42B	$94.19B	25.88	138,200	Trending News
NVAX Novavax	1.9575 of 5 stars	$10.51 -4.2%	$12.13 +15.4%	+15.7%	$1.80B	$1.12B	N/A	1,990
INVA Innoviva	3.7437 of 5 stars	$21.51 +0.4%	$36.20 +68.3%	+3.5%	$1.58B	$411.33M	3.58	100	News Coverage Analyst Upgrade High Trading Volume
MNKD MannKind	3.5846 of 5 stars	$3.53 -6.4%	$8.97 +154.1%	-22.6%	$1.16B	$348.97M	N/A	400	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, NVAX, INVA, MNKD, and ZBIO

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Novavax?

Summary

How does Emergent Biosolutions compare to Innoviva?

Summary

How does Emergent Biosolutions compare to MannKind?

Summary

How does Emergent Biosolutions compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, NVAX, INVA, MNKD, and ZBIO

How does Emergent Biosolutions compare to Johnson & Johnson?

Does the media refer more to JNJ or EBS?

Do insiders & institutionals hold more shares of JNJ or EBS?

Which has higher earnings & valuation, JNJ or EBS?

Which has more risk & volatility, JNJ or EBS?

Do analysts rate JNJ or EBS?

Is JNJ or EBS more profitable?

Summary

How does Emergent Biosolutions compare to Novavax?

Do analysts recommend NVAX or EBS?

Do insiders and institutionals have more ownership in NVAX or EBS?

Does the media prefer NVAX or EBS?

Is NVAX or EBS more profitable?

Which has more risk & volatility, NVAX or EBS?

Which has better earnings and valuation, NVAX or EBS?

Summary

How does Emergent Biosolutions compare to Innoviva?

Do analysts rate INVA or EBS?

Is INVA or EBS more profitable?

Which has higher earnings and valuation, INVA or EBS?

Does the media prefer INVA or EBS?

Which has more volatility & risk, INVA or EBS?

Do insiders and institutionals have more ownership in INVA or EBS?

Summary

How does Emergent Biosolutions compare to MannKind?

Do analysts prefer EBS or MNKD?

Is EBS or MNKD more profitable?

Which has more volatility & risk, EBS or MNKD?

Do insiders & institutionals believe in EBS or MNKD?

Which has better earnings & valuation, EBS or MNKD?

Does the media favor EBS or MNKD?

Summary

How does Emergent Biosolutions compare to Zenas BioPharma?

Is EBS or ZBIO more profitable?

Do institutionals and insiders hold more shares of EBS or ZBIO?

Does the media favor EBS or ZBIO?

Do analysts recommend EBS or ZBIO?

Which has better valuation and earnings, EBS or ZBIO?

Which has more volatility & risk, EBS or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools